BP plc vs Johnson & Johnson: Strategic Comparison
Key Differences at a Glance
| Field | BP plc | Johnson & Johnson |
|---|---|---|
| Revenue | $189.3B | $94.2B |
| Founded | 1909 | 1886 |
| Employees | 87,800 | 140,800 |
| Market Cap | $80.0B | $612.8B |
| Headquarters | United Kingdom | United States |
Quick Stats Comparison
| Metric | BP plc | Johnson & Johnson |
|---|---|---|
| Revenue | $189.3B | $94.2B |
| Founded | 1909 | 1886 |
| Headquarters | London, United Kingdom | New Brunswick, New Jersey |
| Market Cap | $80.0B | $612.8B |
| Employees | 87,800 | 140,800 |
BP plc Revenue vs Johnson & Johnson Revenue — Year by Year
| Year | BP plc | Johnson & Johnson | Leader |
|---|---|---|---|
| 2025 | $189.3B | $94.2B | BP plc |
| 2024 | $189.2B | $88.8B | BP plc |
| 2023 | $210.1B | $85.2B | BP plc |
Business Model Breakdown
Overview: BP plc vs Johnson & Johnson
This in-depth comparison examines BP plc and Johnson & Johnson across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching BP plc on its own, evaluating Johnson & Johnson, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between BP plc and Johnson & Johnson is widest.
On the headline numbers, BP plc reports annual revenue of $189.3B against $94.2B for Johnson & Johnson, while their respective market capitalizations stand at $80.0B and $612.8B. BP plc is headquartered in United Kingdom and Johnson & Johnson operates from United States, and those different home markets shape how each company competes.
BP plc: BP combines a long operating history with a current strategy shaped by FY2025 financial results, leadership priorities, and competitive pressure.
Johnson & Johnson: Johnson & Johnson began as a medical-products company in the nineteenth century and became a diversified healthcare giant. After the Kenvue separation, it is a more focused healthcare company centered on medicine and medical technology.
Business Models: How BP plc and Johnson & Johnson Make Money
BP plc and Johnson & Johnson pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between BP plc and Johnson & Johnson.
BP plc business model: BP makes money through oil and gas production, LNG and power trading, refining, retail fuels, Castrol lubricants, and selective low-carbon investments. Its model depends on disciplined capital allocation, durable customer or channel relationships, and execution inside markets where scale and trust matter.
Johnson & Johnson business model: Johnson & Johnson makes money by discovering, developing, manufacturing, and selling prescription medicines and medical technologies. Innovative Medicine sells therapies in oncology, immunology, neuroscience, pulmonary hypertension, infectious disease, and cardiovascular/metabolism. MedTech sells surgery, orthopaedics, cardiovascular, and vision products to hospitals, physicians, and healthcare systems.
Competitive Advantage: BP plc vs Johnson & Johnson
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of BP plc stack up against those of Johnson & Johnson.
BP plc competitive advantage: The balance sheet survived a catastrophe that would have ended most companies, and the institution continues to function at scale. BP faces a constellation of challenges that are simultaneously financial, operational, reputational, and existential — and that interact with each other in ways that make navigation exceptionally difficult even for a company of its scale and experience. The most fundamental advantage is BP's portfolio of world-class upstream assets. BP's integrated supply and trading capability is a second major competitive advantage that is widely recognized within the industry but less visible to outside observers. The Castrol brand, operated within the Customers & Products segment, represents a third distinct competitive advantage.
Johnson & Johnson competitive advantage: Johnson & Johnson's advantage comes from scale, R&D depth, global regulatory capability, major oncology and immunology franchises, MedTech breadth, and a large commercial infrastructure.
Growth Strategy: Where BP plc and Johnson & Johnson Are Headed
Future prospects matter as much as current results. The growth strategies below explain how BP plc and Johnson & Johnson each plan to expand from here.
BP plc growth strategy: BP is trying to simplify its portfolio, reduce net debt, sharpen upstream and trading returns, and rebuild investor confidence after several years of strategy and leadership resets.
Johnson & Johnson growth strategy: The company is investing in oncology, immunology, neuroscience, cardiovascular MedTech, electrophysiology, surgery, R&D, acquisitions, and global commercial execution.
Financial Picture: BP plc vs Johnson & Johnson
A closer look at the financial trajectory of BP plc and Johnson & Johnson rounds out the comparison.
BP plc: BP reported $189.3B in FY2025 revenue and $55M in net income/profit attributable to the company or shareholders. In 2025 BP reported $189.335B in sales and other operating revenues, $55M of profit attributable to BP shareholders, and $7.485B of underlying replacement-cost profit.
Johnson & Johnson: Johnson & Johnson's FY2025 sales increased 6.0% to $94.193 billion. Net earnings rose to $26.804 billion, helped by operating performance and other income items. Innovative Medicine generated $60.401 billion in sales, while MedTech generated $33.792 billion.
Company-Specific SWOT Notes
BP plc
BP's Gulf of Mexico deepwater assets — including Thunder Horse, Atlantis, Mad Dog, and the undeveloped Kaskida and Tiber discoveries — represent one of the highest-quality upstream portfolios in the world, with decades of accumulated geological knowledge, esta
BP's gas, power, and oil trading operation — employing more than 3,000 professionals globally — generates an estimated $4 billion of additional annual value through market optimization, arbitrage, and risk management that smaller competitors cannot replicate.
BP's net debt of approximately $24 billion at end-2024 is elevated relative to its peer group and constrains the company's financial flexibility.
BP's repeated revisions to its energy transition targets — including walking back the 40% oil production reduction pledge, reducing low-carbon capital expenditure guidance, and selling offshore wind assets — have created a credibility gap with both ESG-focused
The US Inflation Reduction Act of 2022 created approximately $370 billion in clean energy tax credits and incentives that significantly improve the economics of solar, wind, hydrogen, and biofuel investments in the United States.
The rapid growth of electric vehicle sales globally — with EVs accounting for more than 20% of new car sales in China and more than 15% in several European markets as of 2024 — poses a structural long-term threat to BP's retail fuel volumes and refining asset
Johnson & Johnson
Johnson & Johnson's advantage comes from scale, R&D depth, global regulatory capability, major oncology and immunology franchises, MedTech breadth, and a large commercial infrastructure.
Johnson & Johnson wins through medical trust, R&D scale, global reach, leading drug franchises, MedTech breadth, and commercial execution.
The biggest risk is patent, pricing, litigation, or R&D pressure that weakens growth in key pharmaceutical and MedTech franchises.
The company is investing in oncology, immunology, neuroscience, cardiovascular MedTech, electrophysiology, surgery, R&D, acquisitions, and global commercial execution.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | BP plc | BP plc reports the larger revenue base ($189.3B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Johnson & Johnson | Founded in 1909 vs 1886. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | BP plc | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Johnson & Johnson | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Johnson & Johnson | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
BP plc reports the larger revenue base ($189.3B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1909 vs 1886. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: BP plc or Johnson & Johnson?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: BP plc vs Johnson & Johnson
Is BP plc better than Johnson & Johnson?
Verdict: Between BP plc and Johnson & Johnson, BP plc is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, BP plc comes out ahead in this BP plc vs Johnson & Johnson comparison.
Who earns more — BP plc or Johnson & Johnson?
BP plc earns more with $189.3B in annual revenue versus Johnson & Johnson's $94.2B. BP plc leads on total revenue based on latest verified figures.
Which company has higher revenue — BP plc or Johnson & Johnson?
BP plc reported $189.3B, while Johnson & Johnson reported $94.2B. The revenue leader is BP plc based on latest verified figures.
BP plc revenue vs Johnson & Johnson revenue — which is higher?
BP plc revenue: $189.3B. Johnson & Johnson revenue: $94.2B. BP plc has the larger revenue base of the two companies.
Sources & References
- BP plc Corporate Website
- BP plc Annual Report 2025 - Revenue and Financial Data
- sec.gov
- bp.com
- bp.com
- bp.com
- data.sec.gov
- SEC EDGAR: Johnson & Johnson Annual Filings (10-K, 8-K)
- Johnson & Johnson Corporate Website
- Johnson & Johnson Annual Report 2025 - Revenue and Financial Data
- sec.gov